News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cancer Prevention Pharmaceuticals, Inc. And Tillotts Pharma AG Sign Licensing Agreement For CPP-1X/Sulindac In Europe And Japan


1/10/2014 9:28:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TUCSON, Ariz., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc. (CPP) and Tillotts Pharma AG (Tillotts), a wholly-owned subsidiary of Zeria Pharmaceutical Co., Ltd. (Zeria), are pleased to announce today that the companies have entered into an exclusive licensing agreement for European and Japanese rights to develop and commercialize the combination of CPP-1X/sulindac for the treatment of familial adenomatous polyposis (FAP), an orphan disease, and other gastrointestinal conditions.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES